The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 14, 2021

Primary Completion Date

March 2, 2022

Study Completion Date

March 2, 2022

Conditions

Non-alcoholic Steatohepatitis

Interventions

DRUG

HEC88473 injection

HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen

DRUG

Placebo

Placebo will be administered by subcutaneous injection in the abdomen

Trial Locations (1)

Scientia Clinical Research, Sydney

All Listed Sponsors

lead

Dongguan HEC Biopharmaceutical R&D Co., Ltd.

INDUSTRY